



Mechanisms of drug resistance in cancer: The role of extracellular vesicles. 2 
Authors  3 
Priya Samuel1, Muller Fabbri2, David Raul Francisco Carter1* 4 
Author Affiliations 5 
1. Department of Biological and Medical Sciences. Faculty of Health and Life Sciences. Oxford 6 
Brookes University. Gipsy Lane. Headington. Oxford, England. OX3 0BP.  7 
2. Department of Pediatrics and Microbiology & Molecular Immunology, University of Southern 8 
California-Keck School of Medicine Norris Comprehensive, Cancer Center Children’s Center for 9 
Cancer and Blood Diseases, Children’s Hospital, Los Angeles, CA 90027, USA 10 
 11 
* Corresponding author: 12 
dcarter@brookes.ac.uk  13 
+44(0)1865484216 14 
List of abbreviations 15 
ABC     – ATP binding cassette transporters 16 
BE        – Bystander effect 17 
BMSC  – Bone marrow Stromal cells  18 
CAA     – Cancer associated adipocytes 19 
CAF     – Cancer associated Fibroblasts 20 
EVs      – Extracellular Vesicles 21 
GIPC    – GAIP interacting protein C terminus 22 
MDR1  – Multi drug resistance 1  23 
MRP1  – Multidrug Resistance-Associated Protein 1 24 
MVB  – Multivesicular body 25 
Keywords: Extracellular vesicles, drug resistance, Cancer, microRNAs 26 




Drug resistance remains a major barrier to the successful treatment of cancer. The mechanisms by 2 
which therapeutic resistance arises multifactorial. Recent evidence has shown that extracellular 3 
vesicles (EVs) play a role in mediating drug resistance. EVs are small vesicles carrying a variety of 4 
macromolecular cargo released by cells into the extracellular space and can be taken up into 5 
recipient cells, resulting in transfer of cellular material. EVs can mediate drug resistance by several 6 
mechanisms. They can serve as a pathway for sequestration of cytotoxic drugs, reducing the 7 
effective concentration at target sites. They can act as decoys carrying membrane proteins and 8 
capturing monoclonal antibodies intended to target receptors at the cell surface. EVs from resistant 9 
tumor cells can deliver mRNA, miRNA, long non-coding RNA and protein inducing resistance in 10 
sensitive cells. This provides a new model for how resistance that arises can then spread through a 11 
heterogeneous tumor. EVs also mediate cross-talk between cancer cells and stromal cells in the 12 
tumor microenvironment, leading to tumor progression and acquisition of therapeutic resistance. In 13 
this review, we will describe what is known about how EVs can induce drug resistance, and discuss 14 
the ways in which EVs could be used as therapeutic targets or diagnostic markers for managing 15 
cancer treatment. Whilst further characterisation of the vesiculome and the mechanisms of EV 16 
function is still required, EVs offer an exciting opportunity in the fight against cancer.  17 




In the past few decades there has been a large improvement in the effectiveness of cancer therapy, 2 
which is reflected in rising survival rates [1]. Despite these improvements, many patients will relapse 3 
with a tumor that is refractory to treatment, can metastasise to other tissues and severely reduces 4 
overall survival [2-6]. Our inability to prevent this stems from our incomplete understanding of the 5 
mechanisms by which tumor cells become resistant to the drug used to treat them. It is imperative, 6 
therefore, to fully understand the mechanisms of drug resistance so we can aim to prevent it arising, 7 
or reversing it once it has.  8 
A major difficulty in understanding drug resistance is that the molecular mechanisms that underpin 9 
it are complex and multifactorial [7-11]. Indeed, resistance can arise via alterations in many different 10 
cellular processes, and the cause of resistance in one individual may not be the same as in another. 11 
For example, resistance can arise when proteins that export drugs from the cell are upregulated 12 
[12], or proteins that import drugs into the cell are reduced [13-16]. Such changes reduce the 13 
effective concentration of the chemotherapeutic at the active site, which is often the nucleus. Many 14 
chemotherapeutics work by inducing damage in DNA which leads to apoptosis in dividing cells; when 15 
cells gain the ability to repair the damage more effectively or they lose the ability to recognise the 16 
lesions and signal to the apoptotic machinery then this can cause resistance [17, 18]. Similarly, 17 
defects in the apoptotic machinery itself can render a tumor cell less capable of undergoing 18 
programmed cell death and thus more resistant to the effects of cytotoxic agents [19, 20]. Other 19 
changes can also bring about increases in resistance, such as altered autophagy activity [21], 20 
aberrant cell signalling activity, the unfolded protein response [22, 23]  and epithelial to 21 
mesenchymal transition [24]. The acquisition of resistance by any of these mechanisms can be 22 
underpinned by mutations in the primary DNA sequence, deregulation of epigenetic marks and 23 
other changes in transcriptional processing such as aberrant RNA splicing or editing. Another factor 24 
which has emerged as important in the regulation of resistance is the role of intercellular 25 
communication, and in particular the role of extracellular vesicles (EVs) which will be the focus of 26 
this review.  27 
EVs are small vesicular structures that are released by cells into the extracellular space. A wide 28 
variety of EVs have been described in the literature, including exosomes, microvesicles and 29 
apoptotic bodies (figure 1) [25]. Exosomes are produced when multivesicular bodies (MVBs), which 30 
contain intraluminal vesicles, fuse with the plasma membrane, releasing their vesicular contents into 31 
the extracellular region [26]. Microvesicles, on the other hand, are released when regions of the 32 
plasma membrane bud outwards from the cell before being pinched off as a fully formed vesicle [27, 33 
28]. Apoptotic bodies are vesicles released by cells undergoing programmed cell death. Analysing 34 
EVs is challenging as there is a degree of overlap in the size and content of the different types of 35 
vesicle [25, 29]. Whilst we are beginning to understand the differences in vesicles based on their 36 
proteomic content the issue of vesicle heterogeneity is a major problem in the field [29-31]. For this 37 
reason isolated vesicles are grouped under the catch-all term EVs. Indeed, it is known that EVs can 38 
carry a range of cargo molecules, including miRNAs, long-non-coding RNAs (lncRNAs), mRNAs, and 39 
proteins [25, 32-34]. Extracellular vesicles were originally described as a means by which cells could 40 
remove unwanted cellular material [35]. However, it is now understood that EVs can be taken up by 41 
recipient cells via several uptake pathways and can deliver their cargo into the recipient cells [36]. 42 
This transfer of EVs from donor to recipient cells appears to be an important facet of the 43 
communication that occurs between cells and plays a role in many biological processes [25, 37-40]. 44 
It is not surprising, then, that they are deregulated in diseases and can play a role in many aspects of 45 
cancer progression, including in angiogenesis [41], proliferation [42], evasion of the immune 46 
response [43], regulation of metabolism, avoidance of apoptosis and metastasis [44].  47 
EVs can also play a role in mediating drug resistance (figure 2). Cells that secrete more EVs show 48 
greater levels of resistance, possibly via release of drug which can be packaged into the vesicles [45]. 49 
EVs can also be released carrying cell-surface markers that are targeted by antibody therapies; these 50 
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EVs can act as decoys to bind antibody, thereby shielding the cells from the effects of the 1 
therapeutic [46]. Perhaps most intriguing is the numerous reports that describe how drug-resistant 2 
cells can transfer resistance from once cell to another, including from resistant to sensitive cells. This 3 
clearly has implications for the spread of resistance within a heterogeneous tumor. In this review we 4 
will describe the mechanisms by which EVs can transfer resistance to tumor cells.  5 
EVs as a mechanism of resistance 6 
Several studies have shown that cytotoxic drugs can be sequestered into EVs and released from the 7 
cell, thus preventing build-up of the drug in the nucleus. MCF7 cells (breast cancer) that are resistant 8 
to drugs over-express ABCG2 (an ABC transporter known to confer resistance to multiple drugs) 9 
which localises to EVs and mediates uptake of drugs into vesicles for release [47, 48]. This vesicular 10 
localisation of ABCG2 was dependent on PI3K/Akt signalling [47]. Correlation of a ‘vesicle shedding 11 
index’ (a score obtained by analysing expression of genes known to be contain in EVs) with patterns 12 
of resistance for a range of drugs demonstrated a link between EV output and doxorubicin resistance 13 
[49]. Further analysis shows that cells with higher indexes were better able to remove doxorubicin 14 
from the nuclear compartment and into the extracellular space (via EVs) [49].  Similarly, a drug-15 
resistant subline of an ovarian cell line exported nearly three times as much cisplatin in their EVs 16 
compared to the sensitive parental cells [45]. Treatment of pancreatic cancer cells with gemcitabine 17 
enhanced release of EVs at a rate that was proportional to the measured sensitivity of the cells [50]. 18 
The increased production of EVs allowed more drug to be exported and thus the cells to be more 19 
resistant [50]. The orientation of some drug transporters may also be reversed in the membrane of 20 
EVs, which would allow these proteins to pump drugs into the vesicles rather than out, consistent 21 
with a role in mediating expulsion of the drugs in EVs and thus in mediating resistance [51]. 22 
Sequestration of cytotoxic compounds by EVs is therefore another potential mechanism by which 23 
tumors can gain resistance to therapy.  24 
Fascinatingly, EVs may also act as decoys for antibody-based therapies. The use of monoclonal 25 
antibodies to target proteins and receptors at the surface of cancer cells is an expanding field. Whilst 26 
resistance to such therapies can arise through several routes, one emerging mechanism is the 27 
release of the targeted surface marker from the cell via EVs. For example, immunotherapy against 28 
CD20 can help to treat malignant lymphoma, but release of EVs bearing CD20 effectively shield the 29 
cells from antibody-mediated attack, in a process which required ABCA3, a drug transporter from 30 
the ABC (ATP-binding cassette) family of transporters[46]. Similarly, release of EVs carrying HER2 31 
from cells which over-express this oncogene can interfere with the ability of Trastuzumab (the 32 
therapeutic antibody that binds HER2) to inhibit proliferation in breast cancer cells [52].  33 
Proteomic analysis of EVs can give insight into mechanisms of drug resistance 34 
The application of proteomic technology to analyse the protein content of EVs can give insight into 35 
the mechanisms by which EVs can cause resistance, and could also be used to identify biomarkers 36 
for the status of a tumour. A range of techniques can be used to analyse the vesiculome, including 37 
gel-based proteomics (in which proteins are separated on a gel and excised bands are analysed by 38 
mass spectrometry (MS), for example) and gel-free approaches (where total proteins are 39 
fragmented and analysed using techniques such as mass spectrometry) [53]. A comprehensive 40 
proteomic analysis of multiple cell types suggests that EV protein content closely reflects the cellular 41 
source of origin, suggesting that they offer a good indicator of cellular condition [54]. Exosomes 42 
released by apoptosis-resistant acute myeloid leukemia (AML) cells contain differences in their 43 
proteome, compared to those released by sensitive AML cells. Some of these proteins, which were 44 
related to processes including apoptosis and splicing, could be transferred between cells [55]. 45 
Proteomic analysis of EVs from prostate cancer cells that were sensitive or resistant to taxane 46 
revealed an upregulation of integrin β4 and vinculin in the EVs from resistant cells [56]. Similarly, 47 
another study showed that EVs from prostate cancer cells that were docetaxel resistance differed in 48 
their protein content compared to those released by sensitive cells. Interestingly MDR1, MDR3, 49 
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Endophilin-A2 and PABP4 were up-regulated in EVs from resistant cells [57].  MDR1, MDR3 and 1 
PABP4 were also upregulated in the sera of a small sample of three patients with resistant prostate 2 
cancer [57], suggesting they could be used as a biomarker to predict treatment response. Proteomic 3 
analysis of EVs could also predict likelihood of side effects of treatment; one study showed that a 12-4 
protein signature in serum EVs predicts the likelihood of chemotherapy-induced peripheral 5 
neuropathy in breast cancer patients [58]. Proteomics can therefore give an important insight into 6 
the mechanisms by which EVs could contribute to drug resistance.  7 
Transfer of EV protein can cause transfer of drug resistance 8 
In addition to their apparent role in mediating intrinsic resistance to drugs in cells, EVs have been 9 
observed to transfer resistance from one cell to another [59]. The transfer of vesicular protein 10 
between cells is one potential mechanism that could mediate these effects. The best characterised 11 
specific example is the transfer of P-glycoprotein (P-gp) between cells, with numerous groups 12 
around the world reporting their observations that P-gp transfer via vesicles can mediate resistance 13 
in recipient cells [60-70]. P-gp (ABCB1) is an ATP-binding cassette (ABC) transporter that can export 14 
drugs from cells with a broad range of specificity [71]. It is mainly expressed in epithelial cells lining 15 
organs such as the small intestine, colon and lungs, and it plays an important role in allowing these 16 
cells to act as a physiological barrier by pumping out xenobiotic and toxic substances [72]. Higher 17 
levels of P-gp (which can occur naturally, particularly in cancers arising from epithelial tissue at 18 
physiological barriers, or can occur after mutations or as a response to treatment [73, 74]) in tumors 19 
are associated with resistance to a range of compounds, and gives the gene its other name, 20 
Multidrug Resistance 1 (MDR1) [71]. Transfer of P-gp via EVs mediates resistance (for examples see 21 
table 1) and may also involve the action of other proteins that are transferred, such as Ezrin, Radixin, 22 
Moesin and CD44 [67]. Multidrug Resistance-Associated Protein 1 (MRP1) also known as ABCC1 is a 23 
related drug efflux transporter that can also be transferred from resistant to sensitive leukaemia 24 
cells, conferring resistance in the recipient cell [75]. In other instances the P-gp protein is not directly 25 
transferred in EVs, but expression is induced in the recipient cell following delivery of a different 26 
protein. For example, MCF7 cells that are resistant to adriamycin transfer the protein TrpC5 (a Ca2+ 27 
permeable cation channel) to recipient cells via EVs, which then stimulates nuclear translocation of 28 
the NFATc3 protein and results in transcriptional activation of the MDR1 (ABCB1) promoter [64]. It is 29 
likely that in future more examples will emerge of vesicular protein transfer that induces resistance 30 
in recipient cells.  31 
Transfer of EV RNA can cause transfer of drug resistance 32 
miRNA 33 
EVs can carry a variety of coding and non-coding RNA cargo. miRNAs are short (19-25 nucleotides) 34 
non-coding RNAs that primarily function by binding to the RNA-induced silencing complex (RISC) and 35 
repressing gene expression via targeting of 3’UTRs of specific mRNAs [76, 77]. They can also function 36 
as ligands to RNA-binding proteins such as Toll-like receptors, leading to the activation of signalling 37 
pathways [78]. They have been implicated in stress response [79] and in cancer progression [76, 80, 38 
81]. Importantly, their deregulation can promote drug resistance in tumors of different origins [82]. 39 
It is therefore not surprising that miRNAs transferred via EVs may play a role in mediating the 40 
transfer of resistance from one cell to another  41 
Transfer of miRNAs can occur between docetaxel-resistant MCF7 cells and their sensitive parental 42 
line [83-85]. These miRNAs can cause downregulation of target genes in the recipient cells [83]. 43 
RNase treatment of the vesicles abrogates the transfer of resistance, suggesting RNA molecules are 44 
important in the mediation of the effect [83]. Transfer of miR-21, miR-27a and miR-451 from a 45 
chronic myeloid leukemia cell line to MCF7 cells led to increased resistance, possible via activation of 46 
Akt signalling [66]. EVs from a cisplatin-resistant ovarian cancer cell line (CP70) can transfer 47 
resistance to the sensitive parental line (A2780) via vesicular transfer of miR-214 and miR-21-3p, 48 
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which induce resistance by repressing PTEN [86] and NAV3 [87], respectively. miRNA-155 in EVs 1 
from gemcitabine-resistant pancreatic cancer cells can induce resistance when taken up by sensitive 2 
recipient cells; miR-155 induces this resistance by targeting the pro-apoptotic gene TP53INP1 [88]. 3 
Transfer of miR-96 in lung cancer cells (from H1299 to A549 cells)  may cause resistance to cisplatin 4 
that is mediated by targeting of the LIM-domain only protein 7 (LMO7) [89]. Another study with the 5 
same pair of cells showed that transfer of miR-222 may be involved in mediating resistance to 6 
adriamycin [90]. miR-221/222 can be transferred from tamoxifen resistant MCF7 to the sensitive 7 
parental cells leading to acquisition of resistance, possibly via targeting of P27 and ERα [91]. Taken 8 
together these studies show that transfer of extravesicular miRNA is one of the mechanism by which 9 
resistance can spread between cells.  10 
mRNA and long non-coding RNAs (lncRNAs) 11 
In addition to carrying miRNAs it is known that EVs can contain many other species of RNA, including 12 
coding mRNAs and lncRNAs. It is known that mRNAs can be transferred into recipient cells and 13 
actively translated into functional protein [32]. In addition to transferring P-gp protein to recipient 14 
cells, many resistant lines can produce EVs carrying MDR1 (ABCB1) or MRP1 (ABCC1) mRNA which 15 
can be transferred into sensitive cells to induce resistance [61, 66, 69, 75, 85]. A recent study 16 
highlighted the complexity of relationship between mRNAs and miRNAs delivered using leukaemia 17 
cell line CCRF-CEM and its multidrug resistant derivatives VLB100 and E1000 [92]. The authors showed 18 
that ABCB1 (also known as MDR1), ABCC1 (also known as MRP1) and miR-326 can all be delivered in 19 
EVs, but that expression of ABCB1 dominates whilst miR-326 represses ABCC1. If ABCB1 is knocked 20 
down then miR-326 represses ABCC1 less efficiently, suggesting a complex interplay between RNA 21 
delivered in EVs. 22 
LncRNAs are long transcripts that are not translated into proteins and are emerging as important 23 
regulators of function in cells [93, 94]. They have also been linked to cancer progression and 24 
acquisition of drug resistance in tumor cells [95]. Examples are emerging of lncRNAs mediating drug 25 
resistance via transfer in vesicles. The lncRNA linc-ROR can be upregulated by TGFβ or by 26 
chemotherapy, and when transferred via vesicles can induce resistance to sorafenib or doxorubicin 27 
in recipient HepG2 (hepatocellular carcinoma) cells [96]. Similarly the transfer of linc-VLDLR induces 28 
resistance in neighbouring hepatocellular carcinoma cells by increasing levels of the drug transporter 29 
ABCG2 [97]. Treatment of sensitive A2780 ovarian cells with EVs from resistant CP70 cells increased 30 
resistance in a miR-214-dependent manner [86]. Interestingly, treatment of the donor cells with 31 
curcumin (a key component of turmeric) caused up-regulation of the lncRNA MEG3 which acted as a 32 
sponge to inhibit miR-214 and thus blunt the ability of CP70 EVs to induce resistance [86]. These 33 
results show that one of the mechanisms of EV-induced resistance is via the transfer of RNA species, 34 
including coding and non-coding RNAs.  35 
The role of lipids in vesicular resistance-transfer 36 
EVs are bound by a bilayer that contains a different balance of lipids compared to normal plasma 37 
membrane. They are enriched in various lipids, including ceramide, sphingomyelin, 38 
phosphatidylcholine, diacylglycerol and gangliosides [98, 99]. Interestingly, ceramide is required for 39 
EV biogenesis and is required for the loading of some of the cargo in vesicles [100, 101]. Ceramide 40 
has also been linked to drug resistance, possibly via P-gp activity and sequestration of drugs in EVs 41 
[40, 100, 102, 103]. A recent study of the lipidomics of EVs released by PC9R cells (a non-small cell 42 
lung cancer cell line resistant to Gefitinib) reveals a number of phospholipids that are over- or under-43 
represented compared to the EVs released by the sensitive parental line PC9 [104]. Another study 44 
showed that artificial EV-like nanoparticles (composed of lipids similar to those found in EVs) could 45 
induce activation of NF-κB in MiaPaCa-2 cells (a pancreatic cell line) which then induces secretion of 46 
the chemokine SDF-1α [105]. This in turn interacts with the CXCR4 receptor on the surface of cancer 47 
cells and induces resistance via Akt signalling [105]. These results suggest that lipid biosynthesis and 48 
signalling may play a role in mediating resistance via transfer of EVs. 49 
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The role of the tumor microenvironment in EV-mediated transfer of drug resistance 1 
Thus far we have discussed the way in which EVs transferred from resistant cancer cells can induce 2 
resistance when taken up by other, more drug-sensitive, cancer cells. However, tumor cells do not 3 
normally grow in isolation. In their native context cancer cells live alongside a variety of other cell 4 
types, which together are referred to as the tumor microenvironment [106]. Cross-talk between 5 
cancer cells and stromal cells has emerged as an important factor in the progression of a tumor 6 
[107]. A variety of stromal cells interact with cancer cells, including cancer associated fibroblasts 7 
(CAFs), tumor associated macrophages and endothelial cells. Indeed, the tumor microenvironment is 8 
now recognised as having at least as much complexity as any other organ. One of the methods by 9 
which cancer and stromal cells communicate is via the exchange of EVs. This EV-mediated 10 
communication, which occurs in a regulated fashion between epithelial cells and stromal cells, can 11 
become corrupted during tumorigenesis and can promote tumor progression and resistance to 12 
therapy [37, 108].  13 
Numerous examples of EV transfer between stromal cells and cancer cells leading to resistance have 14 
now been documented. MSC exosomes could increase resistance of gastric cancer cells to 5’FU 15 
[109]. Treatment of colorectal cancer stem cells (either from patient xenografts or cell lines sorted 16 
for CD133) showed increased resistance (to chemotherapaeutic agents 5-fluorouracil and 17 
oxaliplatin) when treated with EVs from CAFs [110]. Stromal cells can transfer galectin-3 via vesicles 18 
to acute lymphoblastic leukaemia cells that induce endogenous production of further galectin-3 and 19 
NF-kB activation which leads to drug resistance [111]. Bone marrow stromal cells (BMSCs) release 20 
EVs that can induce resistance to bortezomib in multiple myeloma cells [112]. This may involve 21 
activation of survival signalling pathways including JNK, p38, p53 and Akt [112].  RNA in exosomes 22 
from stromal cells can induce resistance in breast cancer cell by triggering signalling via the pattern 23 
recognition receptor RIG-I and via NOTCH3, leading to the activation of a STAT1-dependent antiviral 24 
response [113].  25 
A common theme in the acquisition of drug resistance via EV transfer within the tumor 26 
microenvironment is the transfer of functional miRNAs [114]. For example, cancer associated 27 
adipocytes (CAAs) and fibroblasts (CAFs) transfer vesicular miR-21 to ovarian cancer cells leading to 28 
increased paclitaxel resistance via targeting of the apoptosome component APAF1 [115]. Treatment 29 
of CAFs with gemcitabine leads to increased release of EVs with the capacity to induce resistance in 30 
pancreatic cancer cells by transferring mRNA encoding the resistance factor Snail and also miR-146a 31 
[116]. Mesenchymal stem cells primed by interaction with breast cancer cells release EVs with miR-32 
222/223 that induce quiescence in a proportion of the cancer cells and induce drug resistance [117]. 33 
Bone marrow mesenchymal cells taken from human donors were able to repress proliferation and 34 
increase resistant bone marrow-metastatic cell line derived from MDA-MB-231 breast cancer cells 35 
[118]. The mechanism involved transfer of miR-23b into the recipient cells which repressed the cell 36 
cycle regulator MARCKS [118]. Interestingly, EV-mediated communication can occur in both 37 
directions. For example, neuroblastoma cells release EVs with miR-21 which interact with the Toll-38 
like receptor in monocytes, leading to reciprocal release of EVs from monocytes carrying miR-155, 39 
which in turn enter neuroblastoma cells and repress TERF1 to induce cisplatin resistance [119]. 40 
These results demonstrate that EV-mediated cross-talk within the tumor microenvironment is an 41 
important mechanism by which resistance can be transferred to cells.  42 
Potential role of EV-mediated bystander effects 43 
Another interesting factor in drug resistance is the role of EVs during stress response which could 44 
lead to bystander effects. The bystander effect (BE) is a phenomenon in which cells undergoing 45 
stress can communicate with other cells to coordinate an intercellular response [120]. The BE was 46 
originally described using radiation; when cells are exposed to ionizing radiation they release a 47 
secreted signal which can induce DNA damage when placed onto naïve cells [121]. This effect has 48 
also been observed following treatment of cells with other stress types, including cytotoxic 49 
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chemicals [122, 123] and heat stress [124]. We have recently shown that the BE is mediated by 1 
release and uptake of EVs following irradiation[125], cytotoxic stress [127] or heat [128]. The 2 
observation that BE is evolutionarily conserved implies a potential role in organismal fitness. One 3 
potential benefit to the BE is that the bystander cells, although apparently stressed, are in fact more 4 
robust in the face of future insults. In other words, EVs released from stressed cells can induce an 5 
adaptive response in naïve recipient cells[127-130]. Applied to the cancer therapy setting one could 6 
imagine a situation where in a cohort of tumor cells treatment with radio- or chemotherapy could 7 
induce release of EVs into the extracellular space which could induce an adaptive response within 8 
the population. Evidence of such a model does exist in the literature. For example, treatment of 9 
A549 cells with EVs released by cisplatin-treated A549s increased resistance to cisplatin [131]. 10 
Treatment of pancreatic cells (MiaPaCa and Colo-357) with gemcitabine led to release of EVs with 11 
capacity to induce resistance to gemcitabine [132]. This was partly mediated by transfer of miR-155 12 
which represses DCK (a gemcitabine metabolising enzyme) and transfer of SOD2 and CAT which can 13 
both detoxify reactive oxygen species [132]. Treatment of hepatocellular carcinoma induces 14 
upregulation of lncRNAs in EVs that can cause resistance when placed onto naïve cells [96, 97]. EV-15 
mediated communication during chemotherapy could therefore also be a mechanism by which 16 
resistance arises within the tumor mass.  17 
 18 
Perspective and future directions  19 
The body of work reviewed here provides a compelling case for the role of EVs in mediating drug 20 
resistance. However, many questions remain unanswered. The full range of mechanisms by which 21 
EVs induce resistance has certainly not been fully elucidated, so further work is necessary. For 22 
example, in some studies a role for activation of signalling pathways such as HGF/c-Met/Akt can be 23 
established [133], but not the precise mechanism by which they become activated. In some cases 24 
there is also contradictory evidence; knockdown of MDR1 (ABCB1) in donor cells does not always 25 
have an effect on the transfer of resistance, suggesting that either the role of MDR1/P-gp (ABCB1) 26 
transfer is complex, or that this particular transfer represents one of multiple mechanisms by which 27 
induction of resistance can be achieved by EVs [109]. Other studies suggest that transfer of EVs does 28 
not always lead to increased resistance. For example, in one study using androgen independent 29 
prostate cancer cell line DU-145, transfer of EVs from resistant cancer cells to their parental line did 30 
not induce resistance [57], whereas other studies showed that DU-145 EVs induce resistance [42, 31 
61]. These conflicting results may be due to subtle differences in methodology such as drug 32 
concentration used, incubation time or thresholds set, the type of drug resistance being tested, or 33 
could suggest that EVs have context-dependent effects. For this reason it is important that all results 34 
of EV-transfer experiments are published and that ‘negative’ results are not excluded from the 35 
literature.  36 
Many of the examples described in this review revolve around the role of miRNAs. However, 37 
important questions remain surrounding the association of EVs with miRNAs. Some studies show 38 
that a large proportion of miRNAs released extracellularly into the culture media or circulation may 39 
in fact be non-vesicular and instead associated with other proteins such as Ago2 [134, 135]. Indeed, 40 
recent stochiometric measurements of vesicular miRNAs suggest that most EVs do not actually carry 41 
any miRNAs [136]. This raises the question of whether the numerous reports of EV-mediated 42 
transfer in fact represent transfer of non-vesicular material (which may co-purify with EVs), whether 43 
the EVs do not contain miRNAs luminally but contain the miRNA associated at the vesicular surface, 44 
or whether further quantification is required to determine the stoichiometry of vesicular miRNA. 45 
More work is certainly needed to explore these questions further.  46 
Potential for therapeutic and prognostic applications 47 
Better understanding of the way EVs mediate drug resistance could lead to novel combination 48 
treatments that are more effective. EVs appear to mediate bystander effects that occur following 49 
9 
 
exposure of cells to radiation or cytotoxic drugs; given that these effects include an adaptive 1 
response it should be possible to sensitise cells to treatment if EV transfer is inhibited. Indeed, 2 
treatment of cells with heparin (an EV uptake-inhibitor) can sensitise cells to cisplatin [137], and our 3 
data suggest that this may be due to the inhibition of EV uptake [127].  4 
The vesicular sequestration and expulsion of cytotoxic drugs as a means to achieve resistance could 5 
be targeted by combination therapies. Targeting the drug transporter ABCA3, another member of 6 
the ABC family of drug transporters, (using either shRNAs or the COX inhibitor indomethacin) 7 
reduced exosome biogenesis and increased nuclear retention (and thus effectiveness) of doxorubicin 8 
and pixantrone [138]. Treatment of cells with guggulsterone (a farnesoid X receptor antagonist) and 9 
bexarotene (a retinoid X receptor agonist) induced higher levels of ceramide which in turn 10 
stimulated the release of EVs. These EVs appear to carry ABC transporters (breast cancer resistance 11 
protein BCRP/ABCG2) which is then depleted from the cell and increases the sensitivity of these cells 12 
to subsequent doxorubicin treatment [103]. Knockdown of GIPC (GAIP interacting protein C 13 
terminus) induces autophagy and the release of EVs with elevated levels of ABCG2 [139]. Following 14 
release of these EVs the cells are more sensitive to gemcitabine, though it is possible this is due to 15 
the pleiotropic effects of GIPC knockdown [139]. Treatment of tumor cells with a proton-pump 16 
inhibitor alters pH and induces the release of EVs leading to increased sensitivity to cisplatin [140]. 17 
Taken together these findings suggest that inhibiting or affecting the compartmentalisation of 18 
therapeutics into EVs can lead to redistribution and/or accumulation of drugs in cells, with potential 19 
increased efficacy of treatment.  20 
Greater understanding of the roles of miRNAs could also be used to target EV-mediated resistance. 21 
For example, when tumor cells were treated with a curcumin the level of lncRNA MEG3 in these cells 22 
rose and appeared to sequester miR-214, thus reducing the ability of vesicular miR-214 to induce 23 
resistance in sensitive cells [86]. Treatment of miRNA inhibitors achieved a similar result, suggesting 24 
that pharmaceutically targeting specific miRNAs could block the spread of resistance in cancer [86]. 25 
An alternative approach is to isolate vesicles from cells artificially over-expressing a miRNA or anti-26 
miR that, when transferred via EVs, can induce sensitivity in recipient cells. For example, EVs from 27 
adipose-derived mesenchymal stem cells over-expressing miR-122 (driven by an expression plasmid) 28 
can sensitise hepatocellular carcinoma cells to drug treatment [141].  Similarly, EVs from 29 
mesenchymal stem cells transfected with an anti-miR-9 can induce sensitivity to temozolomide 30 
when taken up by glioblastoma cells [142].  31 
It is also noteworthy that EVs and their content can serve as biomarkers for cancer [143-147]. Given 32 
that there are changes in EV content that could mediate their ability to induce drug resistance when 33 
transferred between cells it is logical that these changes could also serve as a biomarker for the 34 
presence of tumors that are either resistant to specific drugs or harbour the capacity to transfer 35 
resistance [148]. Indeed, many studies have been published aiming to characterise differences in EVs 36 
from sensitive/resistant cultured cancer cells [33, 90, 104, 149] or from the blood of patients with 37 
different responses to therapy [150]. Further development and use of these biomarkers would then 38 
allow clinicians to either alter the therapy choice or, eventually, target both cancer cells and the EV-39 
mediated communication. Better characterisation of the extracellular vesiculome and greater 40 
understanding of the roles of EVs will help to unlock their therapeutic and prognostic potential.  41 
Final remarks 42 
It has become very clear in the last few years that EVs are an important part of the dialogue that 43 
occurs between different cells [25]. Tumor cells also release EVs, allowing them to transfer 44 
macromolecules to other cancer cells or stromal cells in the tumor microenvironment. This transfer 45 
can have a range of phenotypic effects, but ultimately many of these support the growth of the 46 
tumor. Importantly, it can lead to the transfer of resistance from one tumor cell to another. One can 47 
envisage how this would allow resistance across a population of cells in a tumor mass to rise, as 48 
resistance could be acquired in a pocket of the heterogeneous mass and then spread to other cells 49 
10 
 
via the release of EVs. This, then raises the possibility that drug resistance may be modulated by 1 
locally inhibiting EV release or uptake. This offers an exciting new insight into the biology of cancer, 2 
and offers potential therapeutic targets for tackling the acquisition of therapeutic resistance. Further 3 
work must be performed, particularly in vivo, to better elucidate the mechanisms by which transfer 4 
of EVs can induce resistance.  5 
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Figure Legends 15 
 16 
Figure 1: Types of Extracellular vesicles Microvesicles are formed by outward budding of the plasma 17 
membrane which is then pinched off into the extracellular space. Exosomes are formed by 18 
invagination into multivesicular bodies as intraluminal vesicles; these are released by fusion of the 19 
multivesicular bodies with the plasma membrane. Apoptotic bodies are formed during blebbing of 20 
the plasma membrane when cells undergo apoptosis.  21 
Figure 2: Mechanisms by which extracellular vesicles are shown to modulate response to cancer 22 
chemotherapy EVs have been shown in various studies to modulate chemoresistance in cancer cells. 23 
It has been demonstrated that drugs may be sequestered in extracellular vesicles thereby decreasing 24 
the effectiveness of the drug. Another EV-based resistance mechanism involves resistance to 25 
immunotherapy – EVs presenting CD20 on their surface have been shown to act as a decoy, thereby 26 
shielding the cell from immunotherapy using antibodies to CD20. Various studies have shown 27 
transfer of a number of proteins, mRNA, lncRNA, miRNAs and lipids from resistant cells to recipient 28 
cells, thereby bequeathing a degree of drug resistance. The most common of these is the transfer of 29 
drug efflux proteins such as P-gp (ABCB1) and MRP1 (ABCC1) or mRNA encoding these. Several 30 
microRNAs shown to be transferred through EVs are also implicated in increasing drug resistance in 31 
the recipient cells. Another important factor are the EVs released by stromal cells which have been 32 
shown to modulate resistance to cancer chemotherapy by transferring proteins, miRNA and mRNA. 33 




Table 1: Studies showing proteins or mRNA transferred through extracellular vesicles 2 
tissue donor recipient mRNA/ protein drug First author and 
reference 




Bebawy M [62] 
 




Jaiswal R [63] 




Jaiswal R [63] 
breast MCF-7ADM HMEC P-gp/ ABCB1 
protein 
adriamycin Dong Y [64] 
breast MCF-7ADR MCF-7 P-gp/ ABCB1 
protein 
adriamycin Wang X [68] 




Zhang FF [60] 






docetaxel Corcoran C [61] 
breast MCF-7/DOXO MCF-7 P-gp/ ABCB1 
protein 
doxorubicin Pasquier J [65] 
haematopoetic K562 MDR 










de Souza PS [66] 
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TXL2, US7 Galectin-3 Vincristine and 
BMS345541 
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ABCB1 mRNA Multidrug 
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Jaiswal R [85] 
leukaemia VLB100 CEM  ABCB1 mRNA Multidrug 
resistant 
Lu JF [75] 
leukaemia VLB100 CEM  ABCB1 mRNA Multidrug 
resistant 
Lu JF [92] 
Leukaemia E1000 CCRF-CEM ABCC1 mRNA Multidrug 
resistant 





CAF1 L3.6 Snail mRNA Gemcitabine Richards KE 
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